Eye docs confront Genentech exec

Put a Genentech executive and a bunch of angry ophthalmologists in the same room, and what do you get? Fireworks. At a conference over the weekend, the company's president of product development, Susan Desmond-Hellman, defended its decision to stop selling Avastin to compounding pharmacies, which repackage the drug for use against macular degeneration.

Desmond-Hellman blamed the move on the FDA, saying, "[w]e had no choice." The FDA's worries about repackaging the cancer med could "put our entire manufacturing operation at risk." That's funny, the eye docs responded. The FDA told us different.

Genentech believes eye docs will still be able to get Avastin for their WMD patients. And Desmond-Hellman vigorously denied that the move was meant to steer patients toward the company's designated WMD drug Lucentis, which runs $2,000 a dose compared with $40 for Avastin.

- read the release from the American Academy of Ophthalmology
- see this the item and from the Wall Street Journal's Health Blog
- read the report from OSN SuperSite

Related Articles:
Genentech rethinks Avastin limits. Report
Why should Medicare pay for Lucentis? Report
Genentech cuts eye docs out of Avastin. Report
Doctors balancing effects, costs of Lucentis and Avastin. Report
Lucentis gets the green light from regulators. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.